A multicenter, randomized, open-label phase II trial evaluating the association of Gadolinium-based nanoparticles (AGuIX) with radiotherapy for the therapeutic management of patients with progressive / recurrent inoperable musculoskeletal tumor lesion
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Gadolinium chelated polysiloxane based nanoparticle (Primary)
- Indications Malignant melanoma; Renal cancer; Sarcoma
- Focus Therapeutic Use
- Acronyms NANO-RT-MSK
- 15 Jul 2024 New trial record